Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. - Wikidata - wikimedia - TriplyDB

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.

http://www.wikidata.org/entity/Q34570210

about

Recent progress in pancreatic cancer Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma Curcumin AntiCancer Studies in Pancreatic Cancer Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment Systemic Chemotherapy in Advanced Pancreatic Cancer Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles Systemic treatment for inoperable pancreatic adenocarcinoma: review and update Systemic therapies for pancreatic cancer--the role of pharmacogenetics Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer.Pancreatic cancer treatment and research: an international expert panel discussion.Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma Genetic factors affecting patient responses to pancreatic cancer treatment FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature Metastatic pancreatic cancer: Is there a light at the end of the tunnel?Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis Equilibrative nucleoside transporters-A review.Clinical Translation of Nanomedicine.A novel microfluidic 3D platform for culturing pancreatic ductal adenocarcinoma cells: comparison with in vitro cultures and in vivo xenografts Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison.Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses.Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis.Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer.Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I(131) KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma.Neoadjuvant gemcitabine-based accelerated hyperfractionation chemoradiotherapy for patients with borderline resectable pancreatic adenocarcinoma.Intravenous ω-3 Fatty Acids Plus Gemcitabine.Triplet cytotoxic chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced pancreatic cancer Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice.Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis.Evolution of systemic therapy for advanced pancreatic cancer.The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer.

P2860

Q24626346-3249E902-1CF5-4E88-A567-0F9BD5BAD734 Q24627664-4210D796-7CF8-419A-831B-47926C81CBCD Q26738714-3DD9306E-7268-45EC-A752-D90C0F8C0EBD Q26740619-68AC1F22-1A59-439E-B260-BFAA2990D99C Q26750440-5A3CF163-9364-4B8B-A827-E02FDF820D6D Q26799714-26DBF016-9708-43AA-AB4B-1892D4CE7450 Q26828959-F37E3060-3F34-4147-8E40-1EA883142F97 Q26830913-9E6FC9E8-A6A1-4F23-9C58-0DC842A90C3E Q27021716-BA84FAA7-4657-454C-BB06-7FB05E5156A8 Q27308683-C17DE4C3-DA9C-4C0E-AEAB-69B1116176E4 Q27690868-C13C5FCB-0DCB-42EF-A3ED-4BBD63001458 Q28074614-3B8CF3CA-138F-4B26-8E1B-B3AFDFCE7F87 Q28075293-E3220985-296D-4941-B8E4-23E47C251089 Q28075540-33CC54A5-DBD8-44C5-964C-0AC941751D52 Q28077772-22E5395A-D321-491E-9B74-7A11DFAA58E0 Q28082919-5C156689-8453-4A9D-8F3E-1B70D8870678 Q28487656-303C5F39-2C7D-449C-A103-BE2A2E0A686F Q30244329-333D343C-3143-426A-BEC9-176D9133D8A3 Q30355939-EF53E47D-EFE8-4DF3-BAD8-A6540E34DDAB Q30850662-122E5EA6-82BE-422A-8469-04014761D7C9 Q33326148-E7ADADFB-1BEB-418F-9D4D-B9530DEF1E42 Q33350085-75F3B70D-AFCA-4C6F-B64B-B236EA029545 Q33380084-635D2D4D-54D2-4A80-942A-F2E4EBA2E8A9 Q33384793-1FDC65D1-3E4E-4F12-99A2-745CD62307AE Q33388392-049103F9-CCFA-4516-BA1D-C219E706E2B8 Q33396763-89C03A2D-B6DF-4F68-9544-BF633C1F9468 Q33403498-2FC7F0D2-FD21-460D-8B69-B2007E6E0F1C Q33409519-11992BFF-49C7-4FB6-8280-84E107128D1D Q33412585-B588AD36-794D-4457-AB07-D3F8A9A8B49E Q33418870-DC2BAE25-3D07-4DD2-90BE-8A1E3BC45968 Q33424793-CC070F34-900D-4F4A-A538-2BFD0A2017EE Q33428016-78CDDA14-9434-443F-8B73-7E8607294CB2 Q33430378-B91BD3FB-4DE7-4E5F-A0AC-9CCE38B8970C Q33432931-908D662A-799F-42EF-9761-903028FE0822 Q33435134-2639209F-16EA-4AE5-BDEB-80B6E5A511CD Q33440500-6F5FF213-899F-4DC4-ACDB-E41B2B92342E Q33442676-DE49F533-3626-465B-9C8C-0B6BA43C5E05 Q33557413-5497088A-4098-4BCA-BBA3-6EED5C4D10F9 Q33563635-2860395B-DA4D-48A8-9614-5C439AB2C629 Q33632330-6993B432-F042-48EE-A461-49CC4593DB95

P2860

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.

http://www.wikidata.org/entity/Q34570210

description

2006 nî lūn-bûn

@nan

2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Randomized phase III trial of ...... in advanced pancreatic cancer.

@ast

Randomized phase III trial of ...... in advanced pancreatic cancer.

@en

Randomized phase III trial of ...... in advanced pancreatic cancer.

@nl

type

label

Randomized phase III trial of ...... in advanced pancreatic cancer.

@ast

Randomized phase III trial of ...... in advanced pancreatic cancer.

@en

Randomized phase III trial of ...... in advanced pancreatic cancer.

@nl

prefLabel

Randomized phase III trial of ...... in advanced pancreatic cancer.

@ast

Randomized phase III trial of ...... in advanced pancreatic cancer.

@en

Randomized phase III trial of ...... in advanced pancreatic cancer.

@nl

P1433

Q34570210-7CC7616D-931C-4DD3-877E-40A986DB76D4

P1476

Q34570210-235BC8C4-9B30-4177-8A1B-879C35EFBB34

P2093

Q34570210-06C9B78A-7B7D-4BBA-B10F-FD7773B27B71

Q34570210-10DDCDD2-707C-4EDE-891C-3BBA13F16FC9

Q34570210-1330DC8C-0D2B-4156-A99E-747B07A36AD6

Q34570210-3A68090E-4030-4C86-81A8-6C903C35BB37

Q34570210-4EDCCAFD-173C-4450-8AE9-C4506F92403D

Q34570210-5D01CB64-5B20-4C4C-B033-EC8AFF3A7657

Q34570210-60B23BBB-6C18-463C-ABB2-B81DBE337FA7

Q34570210-6DB76463-BC4F-40CD-8D3D-A210E7CA8C00

Q34570210-78E8029F-05BF-499D-86E0-8437123ABD7D

Q34570210-8B54E513-B81A-465F-BE88-BC427DBD0495

P304

Q34570210-67652293-D79E-433A-9D5F-D4EAF1242483

P31

Q34570210-F7BB9220-9E90-4A73-BE21-BDF37CA064DE

P356

Q34570210-C004294C-C3AD-493B-9ADC-948F5FDBB02F

P407

Q34570210-E574B066-2088-4089-A96B-A6F8C3848A42

P433

Q34570210-3FBE026B-96E3-490A-91F4-EFD7427AE1D7

P478

Q34570210-77C7233F-E665-4436-B51D-BED397B40C44

P50

Q34570210-122B68CA-5BE6-4CE3-861A-E063E4AFFEE0

Q34570210-BA74DCF7-785A-43D8-87EE-535CC0CC1F40

Q34570210-DA2F2BCB-043D-4477-9D05-DBD5EA57853B

P577

Q34570210-B3D1FCE9-8E73-4A0A-8F15-E47177069495

P698

Q34570210-1EC6B477-08EB-4F88-9F80-78D44D7A53E5

P921

Q34570210-C304CDDF-11C3-4F6A-9F8D-D6F08CDFF1DB

P356

JCO.2005.05.1490

P1433

Journal of Clinical Oncology

P1476

Randomized phase III trial of ...... in advanced pancreatic cancer.

@en

P2093

Andreas Rost

http://www.w3.org/2001/XMLSchema#string

Andreas Schalhorn

http://www.w3.org/2001/XMLSchema#string

Axel Hinke

http://www.w3.org/2001/XMLSchema#string

Axel Holstege

http://www.w3.org/2001/XMLSchema#string

Bernard Heinrich

http://www.w3.org/2001/XMLSchema#string

Caroline Haag

http://www.w3.org/2001/XMLSchema#string

Detlef Quietzsch

http://www.w3.org/2001/XMLSchema#string

Dirk Uthgenannt

http://www.w3.org/2001/XMLSchema#string

Doris Fleckenstein

http://www.w3.org/2001/XMLSchema#string

Herbert Schönekäs

http://www.w3.org/2001/XMLSchema#string

P304

3946-3952

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.05.1490

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Hermann Einsele

Ursula Vehling-Kaiser

P577

2006-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16921047

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial